About ARI

Apollo Research and Innovations (ARI) is the research division of Apollo Hospitalsgroup. ARI focuses on scouting, evaluating, deploying and integrating innovations across Apollo Hospitals, with an objective of improving outcomes, affordability and accessibility for our patients. Innovations span across drugs, devices, healthcare software or consumer goods of clinical relevance. ARI provides an end to end platform for converging clinical insights, technology and business to spawn innovation & research within the Apollo Hospitals ecosystem. The vision of ARI is to foster innovation in Technology, Therapy, Processes and Business models to achieve greater access, affordable costs and global quality standards. Some of the key areas of innovations include Convergence of Healthcare with Life Sciences & Technology, Innovation in Software, Innovation in Medical devices and Innovation in Public Health.

ARI currently has a comprehensive ecosystem to undertake clinical studies for sponsored drug trials, devices, software as well as consumer goods. ARI currently is India’s first and single largest clinical site solutions organization having undertaken over 1150 clinical studies, conducted by a dedicated team of 80 trained and experienced clinical research professionals located across 17 sites in 10 various Apollo Hospital locations over 10 therapeutic disciplines. This competence has been further evolved to extend co-development capabilities and augment the same with some very creative business models.

The uniqueness of ARI is the AAHRPP accreditation to 13 of the Apollo Hospitals, which is the gold seal for clinical research, ensuring continuous patient safety throughout the research process. The ethics committees are registered with DCGI, the regulatory body of India and are also NABH certified.
ARI works across a diverse set of focus areas namely – Clinical studies, Clinical research training program, Evaluation and/or pre-market validation studies, Device and software validation studies and co-development, basic and translational research, public health studies, personalized medication and healthcare innovation through creative collaborations.

bg-image

Vision

The vision of ARI is to foster innovation in Technology, Therapy, Processes and Business models to achieve greater access, affordable costs and global quality standards. Some of the key areas of innovations include Convergence of Healthcare with Life Sciences & Technology, Innovation in Software, Innovation in Medical devices and Innovation in Public Health.

Work Scope


ARI works across a diverse set of focus areas namely – Clinical trials, Clinical research training program, pre-market validation studies, Device and software validation studies and co-development, basic and translational research, public health studies, personalized medication and healthcare innovation through creative collaborations.
ARI has introduced many cutting-edge initiatives - assessment of one`s Genetic Predisposition is one such step to personalizing healthcare for an individual. We have introduced a genetic predisposition test as part of Apollo`s personalized health checks (PHC) -a single test to analyse & assess unique DNA makeup of the patient, to find out what conditions they are more prone to. Genetic Predisposition DNA tests can be done for over 60 conditions including Cardiovascular, Diabetes, and Cancer. By monitoring a patient’s pre-disposition and combining it with his current clinical assessment, physicians can personalize advice given to a patient in terms of their diet, exercise, general lifestyle, the frequency of specific tests and doctor consultations so as to stay healthy.

ARI has introduced many cutting-edge initiatives - assessment of one`s Genetic Predisposition is one such step to personalizing healthcare for an individual. We have introduced a genetic predisposition test as part of Apollo`s personalized health checks (PHC) -a single test to analyse & assess unique DNA makeup of the patient, to find out what conditions they are more prone to. Genetic Predisposition DNA tests can be done for over 60 conditions including Cardiovascular, Diabetes, and Cancer. By monitoring a patient’s pre-disposition and combining it with his current clinical assessment, physicians can personalize advice given to a patient in terms of their diet, exercise, general lifestyle, the frequency of specific tests and doctor consultations so as to stay healthy.

Another revolutionary initiative was the introduction of Liquid Biopsy, rated as one of the top 10 ground-breaking technologies in the world by MIT Technology Review in 2015.

Thereafter Apollo in collaboration with its partners introduced liquid biopsies as part of its precision oncology program, a treatment designed specifically for diagnosis of different types of cancer. This has paved the way towards the development of more exosome-based diagnostics by providing clinicians non-invasive tools for prognosis, diagnosis, cancer recurrence, and therapy personalization.

One of the other key areas of innovation Apollo is pursuing is in the area of cervical cancer. India has one of the highest incidence rates in the world. Apollo is engaged with companies from Israel and U.S which offers technologies that include a urine-based DNA test, optical signature- based probe and an Electrical Impedance Spectroscopy (EIS) based medical device that differentiates between cancerous and pre-cancerous cells.

Apollo thus incubated its Biobank in 2013. This self-sustainable bio-bank leverages on bio-samples from Apollo’s nationwide network of hospitals& has emerged as the country’s single largest biobank. The bio-bank is a catalogued library that systematically archives ethically consented & anonymized patient samples with associated clinical data. The samples are utilized to develop novel diagnostics tests and therapeutics.